Indian Economy News

Pharma major Glenmark gets USFDA nod for generic ophthalmic solution

Glenmark Pharmaceuticals Ltd. announced that it has received final approval from the US Food & Drug Administration (USFDA) for its generic brimonidine tartrate and timolol maleate ophthalmic solution, used to treat increased eye pressure due to glaucoma or other conditions. This approval covers the 0.2%/0.5% strength of the solution, which the USFDA has confirmed as bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2%/0.5%, produced by AbbVie, Inc. Glenmark will distribute the solution in the US through its subsidiary, Glenmark Pharmaceuticals Inc, USA. According to IQVIATM sales data, Combigan ophthalmic solution, 0.2%/0.5%, generated annual sales of approximately US$ 290 million for the twelve months ending March 2024.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.